| Controlled Substance | Drug Code | Schedule |
|---|---|---|
| Meperidine | 9230 | II |
| Meperidine-intermediate-A | 9232 | II |
| Meperidine intermediate-B | 9233 | II |
| Meperidine intermediate-C | 9234 | II |
| Metazocine | 9240 | II |
| Oliceridine | 9245 | II |
| Methadone | 9250 | II |
| Methadone intermediate | 9254 | II |
| Metopon | 9260 | II |
| Dextropropoxyphene, bulk (non-dosage forms) | 9273 | II |
| Morphine | 9300 | II |
| Oripavine | 9330 | II |
| Thebaine | 9333 | II |
| Dihydroetorphine | 9334 | II |
| Opium, raw | 9600 | II |
| Opium extracts | 9610 | II |
| Opium fluid extract | 9620 | II |
| Opium tincture | 9630 | II |
| Opium, powdered | 9639 | II |
| Opium, granulated | 9640 | II |
| Levo-alphacetylmethadol | 9648 | II |
| Opium poppy | 9650 | II |
| Oxymorphone | 9652 | II |
| Noroxymorphone | 9668 | II |
| Poppy Straw Concentrate | 9670 | II |
| Phenazocine | 9715 | II |
| Thiafentanil | 9729 | II |
| Piminodine | 9730 | II |
| Racemethorphan | 9732 | II |
| Racemorphan | 9733 | II |
| Alfentanil | 9737 | II |
| Remifentanil | 9739 | II |
| Sufentanil | 9740 | II |
| Carfentanil | 9743 | II |
| Tapentadol | 9780 | II |
| Bezitramide | 9800 | II |
| Fentanyl | 9801 | II |
| Moramide-intermediate | 9802 | II |

The company plans to import analytical reference standards for distribution to its customers for research and analytics purposes. Placement of these drug codes onto the company's registration does not translate into automatic approval of subsequent permit applications to import controlled substances. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized in 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2023–14728 Filed 7–11–23; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–1225]**

### Importer of Controlled Substances Application: Aurobindo Pharma USA, Inc.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Aurobindo Pharma USA, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before August 11, 2023. Such persons may also file a written request for a hearing on the application on or before August 11, 2023.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator,

8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on April 18, 2023, Aurobindo Pharma USA, Inc., 6 Wheeling Road, Dayton, New Jersey 08810–1526, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
|---|---|---|
| Remifentanil ..... | 9739 | II |

The company plans to import Remifentanil (9739) in bulk form for research and development. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Matthew Strait,**

*Deputy Assistant Administrator.*

[FR Doc. 2023–14759 Filed 7–11–23; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

**[OMB Number 1110–0NEW]**

### Agency Information Collection Activities; Proposed eCollection eComments Requested; Lawful Access Data Collection

**AGENCY:** Federal Bureau of Investigation, Department of Justice.

**ACTION:** 30-Day notice.

**SUMMARY:** The Department of Justice (DOJ), Federal Bureau of Investigation (FBI), Criminal Justice Information Services (CJIS) Division will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection was previously published in the **Federal Register** on April 24, 2023, allowing a 60-day comment period.

**DATES:** Comments are encouraged and will be accepted for 30 days until August 11, 2023.

**FOR FURTHER INFORMATION CONTACT:** If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact: Mr. Edward L. Abraham, Unit Chief, FBI, CJIS Division, Module D–1, 1000 Custer Hollow Road, Clarksburg, West Virginia 26306, phone number 304–625–4830.

**SUPPLEMENTARY INFORMATION:** Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;

—Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

—Enhance the quality, utility, and clarity of the information to be collected; and/or

—Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.,* permitting electronic submission of responses.

Written comments and recommendations for this information collection should be submitted within 30 days of the publication of this notice on the following website *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function and entering either the title of the information collection. This information collection request may be viewed at *www.reginfo.gov.* Follow the instructions to view Department of Justice, information collections currently under review by OMB.

DOJ seeks PRA authorization for this information collection for three (3) years. OMB authorization for an ICR cannot be for more than three (3) years without renewal. The DOJ notes that information collection requirements submitted to the OMB for existing ICRs receive a month-to-month extension while they undergo review.

**Overview of This Information Collection**

1. *Type of Information Collection:* New collection.

2. *Title of the Form/Collection:* Lawful Access Data Collection.

3. Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: There is no form number for this collection. The applicable component within the Department of Justice is the CJIS Division, in the FBI.

4. *Affected public who will be asked or required to respond, as well as a brief abstract:*

*Affected Public:* (State, Local and Tribal Governments) Law enforcement agencies and state/local digital forensic laboratories.

*Abstract:* This collection is needed to collect data on the volume of law enforcement investigations that are negatively impacted by device and software encryption.

5. *Obligation to Respond:* Voluntary.

6. *Total Estimated Number of Respondents:* 19,000.

7. *Estimated Time per Respondent:* 3 minutes, 12 seconds.

8. *Frequency:* 50 times annually.

9. *Total Estimated Annual Time Burden:* 50,967 hours.

Total annual responses = 950,000 [19,000 × 50]

Annual burden = ([(950,000 × 192 seconds)/60]/60) = 50,667 hours

10. *Total Estimated Annual Other Costs Burden:* $0.

If additional information is required, contact: Darwin Arceo, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, United States Department of Justice, Two Constitution Square, 145 N Street NE, 4W–218 Washington, DC 20530.

Dated: July 7, 2023.

**Darwin Arceo,**

*Department Clearance Officer for PRA, U.S. Department of Justice.*

[FR Doc. 2023–14755 Filed 7–11–23; 8:45 am]

**BILLING CODE 4410–02–P**

## DEPARTMENT OF JUSTICE

### Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act

On July 7, 2023, the Department of Justice lodged a proposed consent decree with the United States District Court for the District of Massachusetts in *United States and Commonwealth of Massachusetts* v. *Massachusetts Electric*